Search

Your search keyword '"Dzviga C"' showing total 40 results
Start Over Author "Dzviga C"
40 results on '"Dzviga C"'

2. Recommandations pour la prescription et l’interprétation des examens biologiques utilisables dans le cadre du diagnostic ou du suivi des allergies, disponibles en France. Texte court

Author

Chabane, H., Klingebiel, C., Dalampira, G., Sarrat, A., Lefevre, S., Dzviga, C., Metz-Favre, C., Vitte, J., Nicaise-Roland, P., Seve, E., Palussière, C., Lambert, C., Apoil, P-A., Bouvier, M., Castelain, C., Le Pabic, F., Delebarre-Sauvage, C., Uring-Lambert, B., Garnier, L., Mailhol, C., Bouz, C., Farouz, J.C., Bienvenu, J., Couderc, R., Demoly, P., and Just, J.

Published
2021
Full Text
View/download PDF

3. Recommandations pour la prescription et l’interprétation des examens biologiques utilisables dans le cadre du diagnostic ou du suivi des allergies, disponibles en France. Partie 2 : allergie respiratoire

Author

Chabane, H., Metz-Favre, C., Klingebiel, C., Mailhol, C., Le Pabic, F., Castelain, C., Palussière, C., Uring-Lambert, B., Bouz, C., Dalampira, G., Sarrat, A., Seve, E., Lefevre, S., Dzviga, C., Nicaise-Roland, P., Lambert, C., Bienvenu, J., Couderc, R., Demoly, P., and Just, J.

Published
2021
Full Text
View/download PDF

4. Recommandations pour la prescription et l’interprétation des examens biologiques utilisables dans le cadre du diagnostic ou du suivi des allergies, disponibles en France. Partie 1 : préambule

Author

Chabane, H., Vitte, J., Sarrat, A., Seve, E., Apoil, P.-A., Dalampira, G., Palussière, C., Klingebiel, C., Lefevre, S., Nicaise-Roland, P., Dzviga, C., Lambert, C., Metz-Favre, C., Bouvier, M., Castelain, C., Le Pabic, F., Delebarre-Sauvage, C., Uring-Lambert, B., Garnier, L., Bouz, C., Mailhol, C., Farouz, J.C., Bienvenu, J., Couderc, R., Demoly, P., and Just, J.

Published
2021
Full Text
View/download PDF

6. Recommandations pour la prescription et l’interprétation des examens biologiques utilisables dans le cadre du diagnostic ou du suivi des allergies, disponibles en France. Partie 5 : allergie aux piqûres et morsures d’arthropodes et autres allergies ou pathologies

Author

Chabane, H., Dzviga, C., Lambert, C., Sarrat, A., Lefevre, S., Vitte, J., Dalampira, G., Seve, E., Klingebiel, C., Nicaise-Roland, P., Palussière, C., Bienvenu, J., Couderc, R., Demoly, P., and Just, J.

Published
2021
Full Text
View/download PDF

9. Nouvelles recommandations françaises en biologie de l’allergie, synthèse

Author

Chabane, H., Lefevre, S., Dalampira, G., Dzviga, C., Vitte, J., Sarrat, A., Seve, E., Klingebiel, C., Nicaise-Roland, P., Palussière, C., Lambert, C., Metz-Favre, C., Bouvier, M., Castelain, C., Le Pabic, F., Delebarre-Sauvage, C., Uring-Lambert, B., Garnier, L., Apoil, P.A., Bouz, C., Mailhol, C., Farouz, J.C., Bienvenu, J., Couderc, R., Demoly, P., and Just, J.

Published
2020
Full Text
View/download PDF

12. Urticaire chronique et allergie : rationnel pour une exploration ciblée

Author

Chabane, H, primary, Vitte, J, additional, Dzviga, C, additional, Lambert, C, additional, Sarrat, A, additional, Lefevre, S, additional, Dalampira, G, additional, Seve, E, additional, Klingebiel, C, additional, Nicaise-Roland, P, additional, Palussière, C, additional, Bienvenu, J, additional, Couderc, R, additional, Demoly, P, additional, and Just, J, additional

Published
2022
Full Text
View/download PDF

14. Erratum à l’article « Recommandations pour la prescription et l’interprétation des examens biologiques utilisables dans le cadre du diagnostic ou du suivi des allergies, disponibles en France. Texte court » [Rev. Fr. Allergol. 61 (7) (2021) 436–58]

Author

Chabane, H., primary, Klingebiel, C., additional, Dalampira, G., additional, Sarrat, A., additional, Lefevre, S., additional, Dzviga, C., additional, Metz-Favre, C., additional, Vitte, J., additional, Nicaise-Roland, P., additional, Seve, E., additional, Palussière, C., additional, Lambert, C., additional, Apoil, P.-A., additional, Bouvier, M., additional, Castelain, C., additional, Le Pabic, F., additional, Delebarre-Sauvage, C., additional, Uring-Lambert, B., additional, Garnier, L., additional, Mailhol, C., additional, Bouz, C., additional, Farouz, J.C., additional, Bienvenu, J., additional, Couderc, R., additional, Demoly, P., additional, and Just, J., additional

Published
2022
Full Text
View/download PDF

15. Diagnostic moléculaire de l’eczéma de contact allergique

Author

Lefevre, M.A., primary, Nosbaum, A., additional, Rozières, A., additional, Lenief, V., additional, Mosnier, A., additional, De Bernard, S., additional, Nourikyan, J., additional, Buffat, L., additional, Hacard, F., additional, Ferrier-Lebouedec, M.C., additional, Pralong, P., additional, Dzviga, C., additional, Herman, A., additional, Baeck, M., additional, Nicolas, J.F., additional, and Vocanson, M., additional

Published
2021
Full Text
View/download PDF

16. Long-term safety of icatibant treatment of patients with angioedema in real-world clinical practice

Author

Zanichelli, A., Maurer, M., Aberer, W., Caballero, T., Longhurst, H. J., Bouillet, L., Fabien, V., Andresen, I., Grumach, A., Bygum, A., Blanchard Delaunay, C., Boccon-Gibod, I., Coppere, B., Du Thanh, A., Dzviga, C., Fain, O., Goichot, B., Gompel, A., Guez, S., Jeandel, P., Kanny, G., Launay, D., Maillard, H., Martin, L., Masseau, A., Ollivier, Y., Sobel, A., Aygören-Pürsün, E., Bas, M., Bauer, A., Bork, K., Greve, J., Magerl, M., Martinez Saguer, I., Strassen, U., Papadopoulou-Alataki, E., Psarros, F., Graif, Y., Kivity, S., Reshef, A., Toubi, E., Arcoleo, F., Bova, M., Cicardi, M., Manconi, P., Marone, G., Montinaro, V., Triggiani, M., Baeza, L., Cabañas, R., Gala Ortiz, G., Guilarte, M., Hernandez, D., Hernando de Larramendi, C., Lleonart, R., Lobera, T., Marques, L., Saenz de San Pedro, B., Björkander, J., Bethune, C., Garcez, T., Zanichelli, A., Maurer, M., Aberer, W., Caballero, T., Longhurst, H. J., Bouillet, L., Fabien, V., Andresen, I., Grumach, A., Bygum, A., Blanchard Delaunay, C., Boccon-Gibod, I., Coppere, B., Du Thanh, A., Dzviga, C., Fain, O., Goichot, B., Gompel, A., Guez, S., Jeandel, P., Kanny, G., Launay, D., Maillard, H., Martin, L., Masseau, A., Ollivier, Y., Sobel, A., Aygören-Pürsün, E., Bas, M., Bauer, A., Bork, K., Greve, J., Magerl, M., Martinez Saguer, I., Strassen, U., Papadopoulou-Alataki, E., Psarros, F., Graif, Y., Kivity, S., Reshef, A., Toubi, E., Arcoleo, F., Bova, M., Cicardi, M., Manconi, P., Marone, G., Montinaro, V., Triggiani, M., Baeza, L., Cabañas, R., Gala Ortiz, G., Guilarte, M., Hernandez, D., Hernando de Larramendi, C., Lleonart, R., Lobera, T., Marques, L., Saenz de San Pedro, B., Björkander, J., Bethune, C., and Garcez, T.

Subjects
safety, 0301 basic medicine, real-world, medicine.medical_specialty, Immunology, Brief Communication, Off-label use, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Icatibant, Internal medicine, angioedema, icatibant, Immunology and Allergy, Medicine, Reflux esophagitis, Adverse effect, Pregnancy, Angioedema, business.industry, real‐world, medicine.disease, 030104 developmental biology, 030228 respiratory system, chemistry, Anesthesia, Observational study, Long term safety, medicine.symptom, business
Abstract

The Icatibant Outcome Survey (IOS) is an observational study monitoring safety and effectiveness of icatibant in the real‐world setting. We analyzed safety data from 3025 icatibant‐treated attacks in 557 patients (enrolled between July 2009 and February 2015). Icatibant was generally well tolerated. Excluding off‐label use and pregnancy, 438 patients (78.6%) did not report adverse events (AEs). The remaining 119 (21.4%) patients reported 341 AEs, primarily gastrointestinal disorders (19.6%). Of these, 43 AEs in 17 patients (3.1%) were related to icatibant. Serious AEs (SAEs) occurred infrequently. A total of 143 SAEs occurred in 59 (10.6%) patients; only three events (drug inefficacy, gastritis, and reflux esophagitis) in two patients were considered related to icatibant. Notably, no SAEs related to icatibant occurred in patients with cardiovascular disease, nor in those using icatibant at a frequency above label guidelines. Additionally, no major differences were noted in AEs occurring in on‐label vs off‐label icatibant users.

Published
2017

18. Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey

Author

Bygum A, Caballero T, Grumach A, Longhurst H, Bouillet L, Aberer W, Zanichelli A, Botha J, Andresen I, Maurer M, Delaunay C, Boccon-Gibod I, Coppere B, Du Thanh A, Dzviga C, Fain O, Goichot B, Gompel A, Guez S, Jeandel P, Kanny G, Launay D, Maillard H, Martin L, Masseau A, Ollivier Y, Sobel A, Aygoren-Pursun E, Bas M, Bauer M, Bork K, Greve J, Magerl M, Martinez-Saguer I, Strassen U, Papadopoulou-Alataki E, Psarros F, Graff Y, Kivity S, Reshef A, Toubi E, Arcoleo F, Bova M, Cicardi M, Nconi P, Marone G, Montinaro V, Triggiani M, Baeza M, Cabanas R, Guilarte M, Hernandez D, de Larramendi C, Lleonart R, Lobera T, Marques L, Pedro B, Bjorkander J, Bethune C, Garcez T, and IOS Study Grp

Subjects
Hereditary angioedema, Elderly, Icatibant Outcome Survey, Safety
Abstract

Background: Hereditary angioedema with C1 inhibitor deficiency (C1-INH-HAE) is characterized by recurrent swelling in subcutaneous or submucosal tissues. Symptoms often begin by age 5-11 years and worsen during puberty, but attacks can occur at any age and recur throughout life. Disease course in elderly patients is rarely reported. Methods: The Icatibant Outcome Survey (IOS) is an observational study evaluating the safety, tolerability, and efficacy of icatibant. We conducted descriptive analyses in younger (age < 65 years) versus elderly patients (age >= 65 years). Here, we report patient characteristics and safety-related findings. Results: As of February 2018, 872 patients with C1-INH-HAE type I/II were enrolled, of whom 100 (11.5%) were >= 65 years old. Significant differences between elderly versus younger patients, respectively, were noted for median age at symptom onset (17.0 vs 12.0 years), age at diagnosis (41.0 vs 19.4 years), and delay between symptom onset and diagnosis (23.9 vs 4.8 years) (P

Published
2019

19. The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries

Author

Caballero, T., Aberer, W., Longhurst, H.J., Maurer, M., Zanichelli, A., Perrin, A., Bouillet, L., Andresen, I., Arcoleo, F., Bova, M., Cicardi, M., Cillari, E., Montinaro, V., Marone, G., Blanchard Delauny, C., Boccon‐Gibod, I., Coppere, B., Dzviga, C., Fain, O., Goichot, B., Gompel, A., Guez, S., Jeandel, P.Y., Kanny, G., Launay, D., Maillard, H., Martin, L., Masseau, A., Ollivier, Y., Magerl, M., Baeza, M.L., Cabañas, R., Guilarte, M., Hernández, D., Hernando de Larramendi, C., Lleonart, R., Lobera, T., Marqués, L., Bangs, C., Buckland, M., Grigoriadou, S., Helbert, M., Lorenzo, L., Caballero, T., Aberer, W., Longhurst, H. J., Maurer, M., Zanichelli, A., Perrin, A., Bouillet, L., Andresen, I., Arcoleo, F., Bova, M., Cicardi, M., Cillari, E., Montinaro, V., Marone, G., Blanchard Delauny, C., Boccon-Gibod, I., Coppere, B., Dzviga, C., Fain, O., Goichot, B., Gompel, A., Guez, S., Jeandel, P. Y., Kanny, G., Launay, D., Maillard, H., Martin, L., Masseau, A., Ollivier, Y., Magerl, M., Baeza, M. L., Cabañas, R., Guilarte, M., Hernández, D., Hernando de Larramendi, C., Lleonart, R., Lobera, T., Marqués, L., Bangs, C., Buckland, M., Grigoriadou, S., Helbert, M., and Lorenzo, L.

Subjects
Male, Pediatrics, medicine.medical_specialty, Treatment outcome, Dermatology, Bradykinin, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Icatibant, Original Articles and Short Reports, Bradykinin B2 Receptor Antagonists, media_common.cataloged_instance, Medicine, Humans, In patient, 030212 general & internal medicine, Registries, European union, media_common, Retrospective Studies, business.industry, Significant difference, Angioedemas, Hereditary, Retrospective cohort study, medicine.disease, Urticaria ‐ Angioderma ‐ Pruritus, Europe, Treatment Outcome, Infectious Diseases, 030228 respiratory system, chemistry, Hereditary angioedema, Observational study, Original Article, Female, business
Abstract

Background Hereditary angioedema (HAE) due to C1-inhibitor deficiency (C1-INH-HAE) is a rare, potentially fatal, bradykinin-mediated disease. Icatibant is a bradykinin B2 receptor antagonist originally approved in 2008 in the European Union and 2011 in the United States as an acute therapy option for HAE attacks in adults. Objective To compare demographics, disease characteristics and treatment outcomes of icatibant-treated HAE attacks in patients with C1-INH-HAE enrolled in the Icatibant Outcome Survey across six European countries: Austria, France, Germany, Italy, Spain and the UK. Methods The Icatibant Outcome Survey [IOS; Shire, Zug, Switzerland (NCT01034969)] is an international observational study monitoring the safety and effectiveness of icatibant. Descriptive, retrospective analyses compared IOS country data derived during July 2009–April 2015. Results Overall, 481 patients with C1-INH-HAE provided demographic data. A significant difference across countries in age at onset (P = 0.003) and baseline attack frequency (P < 0.001) was found although no significant differences were found with respect to gender (majority female; P = 0.109), age at diagnosis (P = 0.182) or delay in diagnosis (P = 0.059). Icatibant was used to treat 1893 attacks in 325 patients with majority self-administration in all countries. Overall, significant differences (all P < 0.001) were found across countries in time to treatment [median 1.8 h; median range: 0.0 (Germany–Austria) to 4.4 (France) h], time to resolution [median 6.5 h; median range: 3 (Germany–Austria) to 12 (France) h] and attack duration [median 10.5 h; median range: 3.1 (Germany–Austria) to 18.5 (France) h]. Conclusion These data form the first European cross-country comparison of disease characteristics and icatibant use in patients with C1-INH-HAE who are enrolled in IOS. International variation in icatibant practice and treatment outcomes across the six European countries assessed highlight the need to further investigate the range of country-specific parameters driving regional variations in icatibant use.

Published
2017

22. Recommandations de bonne pratique de prescription et d’interprétation de la biologie de l’allergie : démarche méthodologique d’actualisation 2018 par le groupe de travail de la Société française d’allergologie

Author

Chabane, H., primary, Apoil, P.A., additional, Castelain, C., additional, Bouvier, M., additional, Bouz, C., additional, Dalampira, G., additional, Delebarre-Sauvage, C., additional, Dzviga, C., additional, Farouz, J.C., additional, François, S., additional, Garnier, L., additional, Klingebiel, C., additional, Lambert, C., additional, Lefèvre, S., additional, Le Pabic, F., additional, Mailhol, C., additional, Metz-Favre, C., additional, Nicaise-Roland, P., additional, Palussière, C., additional, Sarrat, A., additional, Sève, E., additional, Uring-Lambert, B., additional, Vitte, J., additional, and Just, J., additional

Published
2018
Full Text
View/download PDF

23. Management of hypersensitivity reactions to iodinated contrast media

Author

Brockow, Knut, Christiansen, C., Kanny, G., Clément, O., Barbaud, A., Bircher, A., Dewachter, P., Guéant, J. L., Rodriguez Guéant, R. M., Mouton Faivre, C., Ring, J., Romano, A., Sainte Laudy, J., Demoly, P., Pichler, W. J., Aberer, W., Ballmer Weber, B. K., Bilo, M. B., Birnbaum, J., Blanca, M., Blõmecke, B., Campi, P., De Weck, A., Drouet, M., Dzviga, C., Fernandez, J., Gomez, E., Kapp, A., Kidon, M., Kowalski, M., Laroche, D., Mertès, M., Merk, H., Moneret Vautrin, D. A., Pascual Marcos, C., Rebelo Gomes, E., Rueff, F., Sanz, M. L., Torres, M. J., Vervloet, D., Wedi, B., MARONE, GIANNI, Brockow, Knut, Christiansen, C., Kanny, G., Clément, O., Barbaud, A., Bircher, A., Dewachter, P., Guéant, J. L., Rodriguez Guéant, R. M., Mouton Faivre, C., Ring, J., Romano, A., Sainte Laudy, J., Demoly, P., Pichler, W. J., Aberer, W., Ballmer Weber, B. K., Bilo, M. B., Birnbaum, J., Blanca, M., Blõmecke, B., Campi, P., De Weck, A., Drouet, M., Dzviga, C., Fernandez, J., Gomez, E., Kapp, A., Kidon, M., Kowalski, M., Laroche, D., Marone, Gianni, Mertès, M., Merk, H., Moneret Vautrin, D. A., Pascual Marcos, C., Rebelo Gomes, E., Rueff, F., Sanz, M. L., Torres, M. J., Vervloet, D., and Wedi, B.

Subjects
medicine.medical_specialty, Allergy, Premedication, Immunology, Drug Hypersensitivity, Iodinated contrast media, Skin test, Immediate reaction, Prevalence, Immunology and Allergy, Medicine, In patient, Iodine Compound, business.industry, Contrast media, Risk Factor, ALLERGIC/HYPERSENSITIVITY, Nonimmediate reaction, Diagnostic test, medicine.disease, Dermatology, Surgery, Skin reaction, business, Diagnosi, Human
Abstract

All iodinated contrast media (CM) are known to cause both immediate (≤1 h) and nonimmediate (>1 h) hypersensitivity reactions. Although for most immediate reactions an allergic hypersensitivity cannot be demonstrated, recent studies indicate that the severe immediate reactions may be IgE-mediated, while most of the nonimmediate exanthematous skin reactions, appear to be T-cell mediated. Patients who experience such hypersensitivity reactions are therefore advised to undergo an allergologic evaluation. Several investigators have found skin testing to be useful in confirming a CM allergy, especially in patients with nonimmediate skin eruptions. If a patient with confirmed allergy to a CM needs a new CM exposure, a skin test negative CM should be chosen and premedication may be tried. However, none of these precautional measures is a guarantee against a repeat reaction. More research focusing on pathomechanisms, diagnostic testing and premedication is therefore clearly needed in order to prevent CM-induced hypersensitivity reactions in the future.

Published
2005

24. The Drug Ambassador Project - The diversity of diagnostic procedures for drug allergy around Europe

Author

Gomes, Eva Rebelo, Pichler, Werner J., Demoly, Pascal, Aberer, Werner, Frew, Anthony J., de Weck, Alain, Ballmer Weber, B. K., Barbaud, A., Bilo, B., Bircher, A., Birnbaum, J., Blanca, M., Blömecke, B., Brockow, K., Campi, P., Dzviga, C., Drouet, M., Eberlein König, B., Fernandez, J., Fuchs, T., Guéant, J. L., Gutgesell, C., Hertl, M., Kanny, G., Kapp, A., Kidon, M., Kowalski, M., Merk, H., Moneret Vaultrin, A. D., Pascual Marcos, C., Przybilla, B., Ring, J., Romano, A., Rueff, F., Sabbah, A., Sainte Laudy, J., Sanz, M., Tas, E., Torres, M. J., Vervloet, D., Wedi, B., Wüthrich, B., MARONE, GIANNI, Gomes, Eva Rebelo, Pichler, Werner J., Demoly, Pascal, Aberer, Werner, Frew, Anthony J., de Weck, Alain, Ballmer Weber, B. K., Barbaud, A., Bilo, B., Bircher, A., Birnbaum, J., Blanca, M., Blömecke, B., Brockow, K., Campi, P., Dzviga, C., Drouet, M., Eberlein König, B., Fernandez, J., Fuchs, T., Guéant, J. L., Gutgesell, C., Hertl, M., Kanny, G., Kapp, A., Kidon, M., Kowalski, M., Marone, Gianni, Merk, H., Moneret Vaultrin, A. D., Pascual Marcos, C., Przybilla, B., Ring, J., Romano, A., Rueff, F., Sabbah, A., Sainte Laudy, J., Sanz, M., Tas, E., Torres, M. J., Vervloet, D., Wedi, B., and Wüthrich, B.

Subjects
Immunology and Allergy, Standardization, Diagnosi, Drug hypersensitivity
Published
2005

25. Diagnosis of immediate allergic reactions to beta-lactam antibiotics

Author

Torres, Maria J, Blanca, M., Fernandez, J., Romano, A., De Weck, A., Aberer, W., Brockow, K., Pichler, Werner J., Demoly, Pascal, Ballmer Weber, B. K., Barbaud, A., Bilo, B., Bircher, A., Birmbaum, J., Blömecke, B., Campi, P., Dzviga, C., Drouet, M., Eberlein König, B., Frew, T., Fuchs, T., Guéant, J. L., Gutgesell, C., Hertl, M., Kanny, G., Kapp, A., Kidon, M., Kowalski, M., Merk, H., Moneret Vautrin, A. D., Pascual Marcos, C., Przybilla, B., Rebelo Gomes, E., Ring, J., Rueff, F., Sabbah, A., Sainte Laudy, J., Sanz, M., Tas, E., Vervloet, D., Wedi, B., Wüthrich, B., MARONE, GIANNI, Torres, Maria J, Blanca, M., Fernandez, J., Romano, A., De Weck, A., Aberer, W., Brockow, K., Pichler, Werner J., Demoly, Pascal, Ballmer Weber, B. K., Barbaud, A., Bilo, B., Bircher, A., Birmbaum, J., Blömecke, B., Campi, P., Dzviga, C., Drouet, M., Eberlein König, B., Frew, T., Fuchs, T., Guéant, J. L., Gutgesell, C., Hertl, M., Kanny, G., Kapp, A., Kidon, M., Kowalski, M., Marone, Gianni, Merk, H., Moneret Vautrin, A. D., Pascual Marcos, C., Przybilla, B., Rebelo Gomes, E., Ring, J., Rueff, F., Sabbah, A., Sainte Laudy, J., Sanz, M., Tas, E., Vervloet, D., Wedi, B., and Wüthrich, B.

Subjects
medicine.medical_specialty, Allergy, Clinical immunology, Immunology, beta-Lactams, Beta-lactam, Drug Hypersensitivity, chemistry.chemical_compound, Risk Factors, Clavulanic acid, medicine, Immunology and Allergy, Humans, Drug reaction, Child, Skin Tests, business.industry, medicine.disease, Dermatology, Anti-Bacterial Agents, chemistry, Interest group, business, Algorithms, medicine.drug, Beta lactam antibiotics
Abstract

Allergic reactions to betalactams are the most common cause of adverse drug reactions mediated by specific immunological mechanisms. Reactions may be induced by all betalactams currently available, ranging from benzylpenicillin (BP) to other more recently introduced betalactams, such as aztreonam or the related betalactamase-inhibitor clavulanic acid (Fig. 1) (1–5). Although the production process of betalactams has improved over the years, the number of reactions has not decreased, M. J. Torres, M. Blanca, J. Fernandez, A. Romano, A. de Weck, W. Aberer, K. Brockow, W. J. Pichler, P. Demoly for ENDA, and the EAACI interest group on drug hypersensitivity Allergy Service, Carlos Haya Hospital, Malaga, Spain; Allergy Service, University La Paz, Madrid, Spain; Allergy Section, Dept. Clin. Med., UMH, Elche, Spain; Allergy Service, Catholic University of Rome, Italy; Fondation Gerimmun, Beaumont 18, CH1700, Fribourg, Switzerland; Department of Environmental Dermatology, Graz, Austria; Klinik und Poliklinik f5r Dermatologie und Allergologie, Muenchen, Germany; Clinic for Rheumatology and Clinical Immunology/Allergy, Inselspital, Bern, Switzerland; Maladies Respiratoires-INSERM U454, Hopital Arnaud de Villeneuve, Montpellier, France

Published
2003

32. Reducing the risk of anaphylaxis during anaesthesia: Guidelines for clinical practice

Author

Mertes, P. M., Laxenaire, M. C., Lienhart, A., Aberer, W., Ring, J., Pichler, W. J., Demoly, P., Decroix, G., Dewachter, P., Guéant, J. L., Guilloux, L., Laroche, D., Leynadier, F., Longrois, D., Malinovsky, J. M., Moneret-Vautrin, D. A., Pecquet, C., Pinaud, M., Tréchot, P., Vervloet, D., Wessel, F., Ballmer-Weber, B. K., Barbaud, A., Bilo, B., Birnbaum, J., Bianca, M., Blömecke, B., Brockow, K., Christiansen, C., Weck, A., Dzviga, C., Drouet, M., Eberlein-König, B., Frew, A. T., Fuchs, T., Guéant-Rodriguez, R. M., Gutgesell, C., Hertl, M., Kanny, G., Kapp, A., Kidon, M., Kowalski, M., Marone, G., Merk, H., Pascual-Marcos, C., Przybilla, B., Rebelo-Gomes, E., Rueff, F., Sabbah, A., Sainte Laudy, J., Sanz, M. L., Tas, E., Romano, A., Torres, M. J., Bettina Wedi, Wüthrich, B., Mertes, Paul Michel, Laxenaire, M. C., Lienhart, A., Aberer, W., Ring, J., Pichler, W. J., Demoly, Pascal, Decroix, G., Dewachter, P., Guéant, J. L., Guilloux, L., Laroche, D., Leynadier, F., Longrois, D., Malinovsky, J. M., Moneret Vautrin, D. A., Pecquet, C., Pinaud, M., Tréchot, P., Vervloet, D., Wessel, F., Ballmer Weber, B. K., Barbaud, A., Bilo, B., Birnbaum, J., Bianca, M., Blömecke, B., Brockow, K., Christiansen, C., De Weck, A., Dzviga, C., Drouet, M., Eberlein König, B., Frew, A. T., Fuchs, T., Guéant Rodriguez, R. M., Gutgesell, C., Hertl, M., Kanny, G., Kapp, A., Kidon, M., Kowalski, M., Marone, Gianni, Merk, H., Pascual Marcos, C., Przybilla, B., Rebelo Gomes, E., Rueff, F., Sabbah, A., Sainte Laudy, J., Sanz, M. L., Tas, E., Romano, A., Torres, M. J., Wedi, B., and Wüthrich, B.

Subjects
Anaesthesia, Skin test, Latex, Anaphylaxi, Neuromuscular blocking agent, Hypersensitivity, Tryptase, Immunology and Allergy, IgE, Histamine, Hypnotic

34. Unique molecular signatures typify skin inflammation induced by chemical allergens and irritants.

Author

Lefevre MA, Nosbaum A, Rozieres A, Lenief V, Mosnier A, Cortial A, Prieux M, De Bernard S, Nourikyan J, Jouve PE, Buffat L, Hacard F, Ferrier-Lebouedec MC, Pralong P, Dzviga C, Herman A, Baeck M, Nicolas JF, and Vocanson M

Subjects
Allergens, Humans, Inflammation, Irritants adverse effects, Patch Tests, Dermatitis, Allergic Contact diagnosis, Dermatitis, Allergic Contact etiology, Dermatitis, Irritant etiology, Dermatitis, Irritant genetics
Abstract

Background: Skin exposure to chemicals may induce an inflammatory disease known as contact dermatitis (CD). Distinguishing the allergic and irritant forms of CD often proves challenging in the clinic., Methods: To characterize the molecular signatures of chemical-induced skin inflammation, we conducted a comprehensive transcriptomic analysis on the skin lesions of 47 patients with positive patch tests to reference contact allergens and nonallergenic irritants., Results: A clear segregation was observed between allergen- and irritant-induced gene profiles. Distinct modules pertaining to the epidermal compartment, metabolism, and proliferation were induced by both contact allergens and irritants; whereas only contact allergens prompted strong activation of adaptive immunity, notably of cytotoxic T-cell responses. Our results also confirmed that: (a) unique pathways characterize allergen- and irritant-induced dermatitis; (b) the intensity of the clinical reaction correlates with the magnitude of immune activation. Finally, using a machine-learning approach, we identified and validated several minimal combinations of biomarkers to distinguish contact allergy from irritation., Conclusion: These results highlight the value of molecular profiling of chemical-induced skin inflammation for improving the diagnosis of allergic versus irritant contact dermatitis., (© 2021 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.)

Published
2021
Full Text
View/download PDF

35. Human peripheral basophils extended phenotype shows a high expression of CD244 immuno-regulatory receptor.

Author

Berger AE, Durrieu C, Dzviga C, Perrot JL, and Lambert C

Subjects
Adult, Aged, Aged, 80 and over, Basophils metabolism, Female, Healthy Volunteers, Humans, Immunoglobulin E immunology, Male, Middle Aged, Signaling Lymphocytic Activation Molecule Family analysis, Young Adult, Basophils immunology, Immunoglobulin E metabolism, Signaling Lymphocytic Activation Molecule Family metabolism
Abstract

Introduction: Basophils play a major physio-pathological role in hypersensitivity related diseases. Basophils express high affinity Immunoglobulin (Ig) E receptors (FcεRI), IgG and complement regulatory. Basophils also have immunoregulatory activity through interaction with T cells. The aim of this study was to look for the expression of markers reflecting the activation status of peripheral Basophil in healthy donors., Method: the study was performed on 29 healthy donors, 62% females with a mean age of 50.1 + 17.0 years. Basophils were identified on their expression of CD123 without HLA-DR and/or CD193 in two 8 colors panels including CD46, CD55, CD59, CD203c, CD32 (FcγRII), CD64 (FcγRIII), CD163, CD137L (4-1BBL), CD252 (OX40L), CD244 (2B4) and CD3 on whole blood. Basophil activation with anti IgE was performed on 14 donors., Results and Discussion: Our results confirmed the Basophil expression of CD123, CD193 and CD203 (the latter is strongly increased under stimulation). Complement regulatory proteins (CD46, CD55, CD59) were expressed at the same levels as on other leukocytes; CD46, CD59 expression being slightly increased under stimulation. CD32 and CD163 scavenger were slightly higher than on lympho and not influenced by activation. CD252 or CD137L were expressed at low levels and significantly induced by stimulation. Most of all, CD244 was highly expressed on Basophils as compared to any other leukocytes in fresh peripheral blood., Conclusions: Our study shows that human resting Basophils express IgE and IgG Fc receptors and check point receptor CD244 that could potentially play a role in their previously reported immunoregulatory activity in sensitization and even in tumor immune escape., (Copyright © 2020. Published by Elsevier B.V.)

Published
2021
Full Text
View/download PDF

36. Immediate Hypersensitivity to Contrast Agents: The French 5-year CIRTACI Study.

Author

Clement O, Dewachter P, Mouton-Faivre C, Nevoret C, Guilloux L, Bloch Morot E, Katsahian S, Laroche D, Audebert M, Benabes-Jezraoui B, Benoit Y, Beot S, Berard F, Berthezene Y, Bertrand P, Bouffard J, Bourrain JL, Boyer B, Carette MF, Caron-Poitreau C, Cavestri B, Cercueil JP, Charpin DA, Collet E, Crombe-Ternamian A, Dalmas J, Decoux E, Defrance MF, Delaval Y, Demoly P, Depriester C, Depriester P, Didier A, Drouet M, Dupas B, Dupre-Goetchebeur D, Dzviga C, Fabre C, Ferretti G, Fourre-Jullian C, Girardin P, Giron J, Gouitaa M, Grenier N, Guenard Bilbault L, Guez S, Gunera-Saad N, Heautot JF, Herbin D, Hoarau C, Jacquot C, Julien C, Laborie L, Lambert C, Larroche P, Leclerc X, Lemaitre L, Leynadier F, Lillo-Le-Louet A, Louvel JP, Louvier N, Lucas MM, Meites G, Mennesson N, Metge L, Meunier Y, Monnier-Cholley L, Musacchio M, Nicolie B, Occelli G, Oesterle H, Paisant-Thouveny F, Panuel M, Railhac N, Rety-Jacob F, Rochefort-Morel C, Roy C, Sarlieve P, Sesay M, Sgro C, Taourel P, Terrier P, Theissen O, Topenot I, Valfrey J, Veillon F, Vergnaud MC, Veyret C, Vincent D, Wallaert B, Wessel F, and Zins M

Abstract

Background: Iodinated and gadolinium-based contrast media (ICM; GBCM) induce immediate hypersensitivity (IH) reactions. Differentiating allergic from non-allergic IH is crucial; allergy contraindicates the culprit agent for life. We studied frequency of allergic IH among ICM or GBCM reactors., Methods: Patients were recruited in 31 hospitals between 2005 and 2009. Clinical symptoms, plasma histamine and tryptase concentrations and skin tests were recorded. Allergic IH was diagnosed by intradermal tests (IDT) with the culprit CM diluted 1:10, "potentially allergic" IH by positive IDT with pure CM, and non-allergic IH by negative IDT., Findings: Among 245 skin-tested patients (ICM = 209; GBCM = 36), allergic IH to ICM was identified in 41 (19.6%) and to GBCM in 10 (27.8%). Skin cross-reactivity was observed in 11 patients with ICM (26.8%) and 5 with GBCM (50%). Allergy frequency increased with clinical severity and histamine and tryptase concentrations (p < 0.0001). Cardiovascular signs were strongly associated with allergy. Non-allergic IH was observed in 152 patients (62%) (ICM:134; GBCM:18). Severity grade was lower (p < 0.0001) and reaction delay longer (11.6 vs 5.6 min; p < 0.001). Potentially allergic IH was diagnosed in 42 patients (17.1%) (ICM:34; GBCM:8). The delay, severity grade, and mediator release were intermediate between the two other groups., Interpretation: Allergic IH accounted for < 10% of cutaneous reactions, and > 50% of life-threatening ones. GBCM and ICM triggered comparable IH reactions in frequency and severity. Cross-reactivity was frequent, especially for GBCM. We propose considering skin testing with pure contrast agent, as it is more sensitive than the usual 1:10 dilution criteria.

Published
2018
Full Text
View/download PDF

37. Antigen 5-spiked Vespula and Polistes venom extracts for Vespid allergy diagnostics: A French multicenter study.

Author

Lambert C, Birnbaum J, Dzviga C, Hutt N, Apoil PA, Bienvenu F, Drouet M, Beauvillain C, Brabant S, Guilloux L, Mariotte D, Lavaud F, Nicaise-Roland P, Tabary T, Sarrat A, and Vitte J

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Animals, Child, Child, Preschool, Female, France, Humans, Hypersensitivity blood, Hypersensitivity immunology, Immunoglobulin E immunology, Infant, Male, Middle Aged, Wasps immunology, Young Adult, Allergens immunology, Hypersensitivity diagnosis, Immunoglobulin E blood, Wasp Venoms immunology
Published
2018
Full Text
View/download PDF

38. Survey on practice of venom immunotherapy in France.

Author

Dzviga C, Matevi C, Bonniaud P, Lavaud F, Girodet B, Birnbaum J, and Lambert C

Abstract

Introduction: Venom immunotherapy (VIT) is the only efficient prevention for sting-induced anaphylaxis, but its application is not without risks and needs precautions and standardization. European guidelines were proposed in 2005, but recent practice surveys and more recent knowledge raise the need for an update. The aim of this study was to analyze VIT practices in France, based on previous surveys in Europe but also extended to outcome event management., Material and Methods: A paper questionnaire was sent widely to persons involved in venom treatment., Results: Eighty-six responses could be included from physicians actively involved in VIT induction evenly distributed in France. The survey shows that VIT was engaged from grade III down to grade I reactions, starting preferentially with the ultra-rush protocol. Premedication was used by 42% only and risks induced by co-treatment with β-blockers were well known but not with angiotensin-converting enzyme inhibitors. However, side effects were very variably managed from arrest to enhancement in doses, time-delay or duration. Similarly, we observed a large discrepancy in treatment evaluation (skin tests, biology, timing and interpretation), decision making for treatment termination (when and how long to be prolonged) and post-treatment follow-up (adrenaline kit, event record) as well as procedures in case of late relapse (new induction, different doses)., Conclusions: Our study shows that most recommendations were fully or partially followed and may need reminding, but many points need to be completed or updated with new tools and knowledge acquired during the last 10 years.

Published
2016
Full Text
View/download PDF

39. [Solar urticaria: one case treated by intravenous immunoglobulin].

Author

Puech-Plottova I, Michel JL, Rouchouse B, Perrot JL, Dzviga C, and Cambazard F

Subjects
Biopsy, Dermatitis, Phototoxic diagnosis, Female, Follow-Up Studies, Humans, Middle Aged, Patch Tests, Skin pathology, Treatment Outcome, Urticaria diagnosis, Dermatitis, Phototoxic therapy, Immunization, Passive, Sunlight adverse effects, Urticaria therapy
Abstract

Background: Solar urticaria is a rare photodermatosis which often begins from the third to the fifth decade. Usual treatment consists of photoprotection measures and antihistamines although disease control is sometimes unsatisfactory with both. We report herein a very severe case of solar urticaria we treated with intravenous immunoglobulins., Case-Report: A 55-year-old woman suffered for 3 years from very severe solar urticaria which resisted treatment. Phototests revealed two action spectra: the first in UVA near 380 nm with a minimal urticarian dose of 0.025 J/cm(2), the second near 500 nm in visible light., Results: As last resort treatment, we gave our patient intravenous immunoglobulins. After the third course of treatment, the improvement was impressive as the patient could tolerate visible light and 15 minutes of intense solar exposure. The minimal urticarian dose was raised from 0.025 J/cm(2) to 27 J/cm(2) in UVA. One year after treatment, the solar urticaria has disappeared., Conclusions: We report herein the first case of solar urticaria treated with success with immunoglobulin. Intravenous immunoglobulin treatment is well for its effectiveness in many autoimmune diseases such as autoimmune thrombocytopenic purpura, and also, as recently proven, in some cases of severe idiopathic chronic urticaria.

Published
2000

40. [Hypersensitivity to Sintrom, caused by cochineal red A].

Author

Guy C, Dzviga C, Genot A, Patural P, and Ollagnier M

Subjects
Acenocoumarol immunology, Adult, Anticoagulants adverse effects, Female, Hemostatics adverse effects, Hemostatics antagonists & inhibitors, Humans, Naphthalenesulfonates, Vitamin K adverse effects, Acenocoumarol adverse effects, Azo Compounds adverse effects, Dermatitis, Allergic Contact etiology, Vitamin K antagonists & inhibitors
Published
1995

Catalog

Books, media, physical & digital resources
See catalog results